Monitoring of QTc in subjects hospitalized for 1 year in an acute psychiatric ward treated with clotiapine and other associated antipsychotics: a retrospective study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Background: Many antipsychotic medications are responsible for prolonging QTc, a risk factor for sudden death, which is one of the main causes of reduced life expectancy in patients with mental health disorders. Objectives: To evaluate the cardiac safety profile of clotiapine in a naturalistic setting. Design: This observational, retrospective study included 70 subjects hospitalized at the Service of Psychiatry Diagnosis and Care in Modena from February 1, 2023 to July 31, 2024, treated with clotiapine. Methods: Demographic and clinical data were collected, along with electrocardiographic measurements (QTc) taken at the start of treatment (T0), after at least 7 days of therapy (T1), and at further follow-up (T2) after 7-21 days. Prolongation was considered when QTc exceeded 500 ms or an increase of 60 ms compared to baseline, according to international standards. Results: = 3.5) of QTc increase at T1 accounted for half of the sample, and only one patient had an increase greater than 60 ms. Conclusion: Clotiapine treatment, also in combination with haloperidol, had minimal prolongation of QTc within the limits of clinical safety. A stabilization of QTc over time was observed, indicating a possible adaptation to treatment. Methodological limitations of this study call for further research.
Fields of Study & Subjects
Cardiac electrophysiology and arrhythmias
Schizophrenia research and treatment
Cardiac Health and Mental Health
Publication details
- Journal / source
- Therapeutic Advances in Drug Safety
- Volume
- 17
- Pages
- 20420986261430214–20420986261430214
- Publication date
- 1 March 2026
- Language
- EN